cagrisema cagrilintide semaglutide phase 3 obesity CagriSema: a novel dual-pathway approach to target and its complications ADA 2025: CagriSema Demonstrates Significant

Peptides, PRP, and topical scalp treatments may help maintain stronger, healthier follicles

Sleep and recovery Sleep quality often improves on semaglutide as weight decreases, particularly for people with obstructive sleep apnea

A peptide that has lost its shape cannot effectively bind to the GLP-1 receptors in your body

What makes retatrutide distinct in this context is its third receptor target: the glucagon receptor (GCGR)

Tirzepatide (Mounjaro, Zepbound) Strengths: Highest efficacy for both glucose control and weight loss Dual mechanism (GLP-1 + GIP) may provide unique benefits Once-weekly dosing Generally well-tolerated Considerations: Higher cost than semaglutide Less long-term safety data (newer medication) Cardiovascular outcome trial not yet complete (though expected to be positive) Best for: Patients prioritizing maximum weight loss

Hyperammonemia Inform patients of the signs and symptoms associated with hyperammonemic encephalopathy and to notify the prescriber if any of these symptoms occur [seeWarnings and Precautions (5.9, 5.10)]